At a glance
- Originator Wakunaga Pharmaceutical
- Class
- Mechanism of Action Immunomodulators; Immunosuppressants; Tumour necrosis factor-alpha convertase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Rheumatoid arthritis; Sepsis; Type 2 diabetes mellitus
Most Recent Events
- 09 Sep 2004 Discontinued - Preclinical for Rheumatoid arthritis in Japan (unspecified route)
- 09 Sep 2004 Discontinued - Preclinical for Sepsis in Japan (unspecified route)
- 09 Sep 2004 Discontinued - Preclinical for Type-2 diabetes mellitus in Japan (unspecified route)